Theravance Biopharma (TBPH) Long-Term Deferred Tax (2014 - 2024)

Theravance Biopharma (TBPH) has reported Long-Term Deferred Tax for 5 consecutive years, with $2.4 million the latest figure, recorded in Q4 2024.

• In Q4 2024, Long-Term Deferred Tax fell 98.41% year-over-year to $2.4 million; the TTM figure through Dec 2024 stood at $2.4 million (down 98.41% YoY), while the FY2024 annual figure was $2.4 million, down 98.41% from the prior year.
• Long-Term Deferred Tax declined to $2.4 million in Q4 2024 per TBPH's latest filing, from $153.2 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $153.2 million in Q4 2023 and bottomed at $2.4 million in Q4 2024.
• Historically, Long-Term Deferred Tax has averaged $99.1 million across 3 years, with a median of $141.7 million in 2022.
• Annual changes were most pronounced in 2023 — Long-Term Deferred Tax gained 8.15% — and 2024, when it plunged 98.41%.
• Theravance Biopharma's Long-Term Deferred Tax stood at $141.7 million in 2022, then rose by 8.15% to $153.2 million in 2023, then slumped by 98.41% to $2.4 million in 2024.
• Business Quant data shows TBPH's Long-Term Deferred Tax at $2.4 million in Q4 2024, $153.2 million in Q4 2023, and $141.7 million in Q4 2022.